Division of Pharmacoengineering and Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
Stem Cell Rev Rep. 2022 Oct;18(7):2474-2493. doi: 10.1007/s12015-022-10375-3. Epub 2022 Apr 19.
The spread of non-small cell lung cancer (NSCLC) to the leptomeninges is devastating with a median survival of only a few months. Radiation offers symptomatic relief, but new adjuvant therapies are desperately needed. Spheroidal, human induced neural stem cells (hiNeuroS) secreting the cytotoxic protein, TRAIL, have innate tumoritropic properties. Herein, we provide evidence that hiNeuroS-TRAIL cells can migrate to and suppress growth of NSCLC metastases in combination with radiation. In vitro cell tracking and post-mortem tissue analysis showed that hiNeuroS-TRAIL cells migrate to NSCLC tumors. Importantly, isobolographic analysis suggests that TRAIL with radiation has a synergistic cytotoxic effect on NSCLC tumors. In vivo, mice treated with radiation and hiNeuroS-TRAIL showed significant (36.6%) improvements in median survival compared to controls. Finally, bulk mRNA sequencing analysis showed both NSCLC and hiNeuroS-TRAIL cells showed changes in genes involved in migration following radiation. Overall, hiNeuroS-TRAIL cells +/- radiation have the capacity to treat NSCLC metastases.
非小细胞肺癌(NSCLC)向软脑膜的扩散是毁灭性的,中位生存时间仅为数月。放射治疗可提供症状缓解,但迫切需要新的辅助治疗方法。分泌细胞毒性蛋白 TRAIL 的球形人诱导神经干细胞(hiNeuroS)具有内在的肿瘤趋向性。在此,我们提供的证据表明,hiNeuroS-TRAIL 细胞可以迁移并与放射治疗联合抑制 NSCLC 转移的生长。体外细胞追踪和死后组织分析表明,hiNeuroS-TRAIL 细胞可迁移至 NSCLC 肿瘤。重要的是,等对数分析表明 TRAIL 联合放射治疗对 NSCLC 肿瘤具有协同细胞毒性作用。在体内,接受放射治疗和 hiNeuroS-TRAIL 治疗的小鼠的中位生存时间与对照组相比有显著(36.6%)改善。最后,批量 mRNA 测序分析表明,NSCLC 和 hiNeuroS-TRAIL 细胞在接受放射治疗后,与迁移相关的基因均发生了变化。总的来说,hiNeuroS-TRAIL 细胞 +/- 放射治疗有能力治疗 NSCLC 转移。